Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate

Most gastrointestinal stromal tumors (GISTs) are caused by activating mutations of the KIT receptor tyrosine kinase. The small molecule inhibitor imatinib mesylate was initially developed to target the ABL1 kinase, which is constitutively activated through chromosomal translocation in BCR-ABL1-posit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Rausch, Jessica L., Boichuk, Sergei, Ali, Areej A., Patil, Sneha S., Lee, Donna M., Brown, Matthew F., Makielski, Kathleen R., Liu, Ying, Taguchi, Takahiro, Kuan, Shih-Fan, Duensing, Anette
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354847/
https://ncbi.nlm.nih.gov/pubmed/27965460
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13882
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky